October 6, 2023

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Takaaki Fukushima
Executive Corporate Officer and Chief Financial Officer
TEL: +81-3-5472-1125

Notice of Agreement to Set up a STraight-Equity Issue Program ("STEP") and Issue New Shares through Third-Party Allotment

TOKYO, Japan, October 6, 2023—SymBio Pharmaceuticals Limited (TSE: 4582) ("SymBio" or the "Company") announced that at a Board of Directors meeting held today, it resolved to enter into an agreement with EVO FUND (the "Allottee") to set up an equity issue program (the "Agreement to Set up an Equity Issue Program"), as outlined below.

The Company also announced that on the same day, its Board of Directors had resolved to issue new shares through a third-party allotment to the Allottee based on the equity issue program established under the Agreement to Set up an Equity Issue Program (the "Program"), as described below.

I. STraight-Equity Issue Program ("STEP")

1. Details of the Program

The Program allows for the issuance of up to 6,000,000 common shares of the Company through third-party allotment to the Allottee based on the Agreement to Set up an Equity Issue Program between the Company and the Allottee.

The Allottee has expressed its willingness, in principle, to accept common shares of the Company allotted to it under the Program. The risk of non-payment cannot be eliminated as the Allottee is not obligated to accept the issue of the shares. However, since the Allotee has never failed to make payments in similar contracts with other companies in the past, the Company has determined it is highly likely that the Allottee will make the payments for the shares issued. Whether each of the allotments described below, from the 1st allotment through the 5th allotment, are executed (below, shares issued in the 1st allotment through the 5th allotment, whether individually or collectively, are referred to as the "Shares," and the issue of the Shares to the Allottee through a third-party allotment based on the Program, whether individually or collectively, are referred to as the "Capital Increase by Third-Party Allotment") are affected by reasons for limiting allotment as of the allotment resolution date associated with that allotment. (Allotment of the Shares may be limited under the following circumstances: in the event of any misstatement, etc., in the securities registration statement or other disclosure documents relating to the issue of the Shares; in the event of any misstatement, etc. in any documents, drawings, audio recordings, or other materials other than disclosure documents prepared by the Company for the offering of the Shares; in the event that undisclosed events or circumstances have occurred since the closing date of the latest audited financial statements that may have a significant adverse impact on the

financial condition and operating results of the Company and the Group; in the event the Capital Increase by Third-Party Allotment conflicts with the internal rules of the Company or the Allottee, or with any agreements already concluded by the Company or the Allottee; in the event of legal proceedings or other procedures in process involving the Company or its subsidiaries that may have a significant impact on the Capital Increase by Third-Party Allotment; in the event of material facts or circumstances as specified in Article 166, Paragraph 2, of the Financial Instruments and Exchange Act that have not been disclosed and, if disclosed, could have a significant impact on our stock price; in the event that the Company relies on the Allottee or its affiliates for the transactions planned under the Program, without acting on its own judgement and responsibility based on professional advice; in the event of any inconsistency between the policy of the Allottee with respect to the holding or disposition of the share certificates and other securities disclosed or announced for the most recent third-party allotment of share certificates and other securities made within five years prior to the date of the conclusion of the Agreement to Set up an Equity Issue Program and the subsequent actions of the Allottee with respect to the holding and disposition of such share certificates and other securities; in the event that the Company or the Allottee or any of their officers or directors fall under the category of antisocial forces; or in the event the Company is unable to obtain an opinion from the Audit & Supervisory Committee to the effect that the issue price of the Shares for the allotment is not particularly favorable to the Allottee on the date of the resolution for the said allotment.) In other words, if there are reasons for limiting allotment at the allotment resolution date associated with an allotment, the Company will not adopt the allotment resolution for that allotment, will withdraw the securities registration statement for that allotment at that time, and will not make that allotment. In such a case, the Company will consider issuing its common shares in relation to a re-allotment. Furthermore, if under the Program a change in capital policy becomes necessary, the Company may choose not to adopt an allotment resolution by notifying the Allottee at least 11 trading days prior to the allotment resolution date for the corresponding allotment.

The total number of common shares of the Company that may be allocated under the Program is 6,000,000. Allocations may be conducted up to five times, in the 1st through 5th allotments. On October 6, 2023, the Company's Board of Directors resolved to introduce the Program and to issue shares for the 1st through 5th allotments, with due dates of payment and quantities of shares to be allocated as indicated in the tables below. The table below indicates the date of the Board of Directors resolution for each allotment (the "Allotment Resolution Date;" the Board of Directors resolution for each allotment is referred to as the "Allotment Resolution"). For each allotment, the corresponding Allotment Resolution indicated in the table below will determine the terms and conditions of the allotment, and a third-party allotment agreement will be executed between the Company and the Allottee after the securities registration statement for the allotment becomes effective. The issue price for each allotment will be the amount equal to the simple average of the closing price of common shares of the Company announced by the Tokyo Stock Exchange, Inc. (the "TSE") during the 10 trading days up to and including the day immediately preceding the Allotment Resolution Date (rounded off to the first decimal place). (However, if there is no closing price for any of the 10 trading days, the Allotee may decide whether to include such a day in the calculation of the issue price.) The Allottee has requested that the price be determined based on a certain level of share price over a certain period of time, rather than using a spot price. As this agreement involves large-scale financing over a period of several months, we have decided to use an average stock price for a certain period of time prior to the Allotment Resolution Date as the issue price for each allotment because we believe this is reasonable under the terms and conditions of the Program. The reason the Company concluded the Agreement to Set up an Equity Issue Program with the Allottee

is to determine in advance the preconditions for the 1st through 5th allotments and in doing so, avoid the time and efforts required for discussing the details of the agreement for each allotment.

	Allotment Resolution Date	Due date of payment	Quantity allocated (Note)
1st allotment	October 25, 2023	November 10, 2023	1,200,000 shares
2nd allotment	December 4, 2023	December 20, 2023	1,200,000 shares
3rd allotment	January 22, 2024	February 7, 2024	1,200,000 shares
4th allotment	February 29, 2024	March 18, 2024	1,200,000 shares
5th allotment	April 3, 2024	April 19, 2024	1,200,000 shares

(Note) Quantities allocated for the 1st through 5th allotments are provisional, as of the date of this release. The final quantity allocated for each allotment from the 1st through 5th allotments will range from 1,200,000 shares to 2,500,000 shares, and the total will not exceed the 6,000,000 shares stipulated for issuance under the Program. Quantities will be determined by the Allottee notifying the Company prior to the Allotment Resolution Date corresponding to each allotment. The STraight-Equity Issue Program (“STEP”) will conclude when the total number of shares issued reaches the upper limit of 6,000,000, at which point any remaining tranches of allotment will be cancelled. The Allottee will determine the quantity of shares to accept based on a comprehensive assessment based on market trends.

2. Reasons, etc., for Introducing the Program

(1) Purpose of Funding through the Program

The purpose of funding through the Program is described below in “II. Issuance of New Shares through Third-Party Allotment, 2. Purposes of and Reasons for the Offer.”

(2) Reason for Selecting the Program as a Funding Method

After comparing and considering various funding methods, we have decided to adopt the Program proposed by the Allottee as the funding method (the “Scheme”), which allows us to raise the necessary funds for future business operations. We believe the Scheme has a stronger likelihood of meeting our financing needs than stock acquisition rights or similar instruments, which are exercised based on stock price movements and the discretion of the allottees. We believe the Scheme will contribute to the continuity and stability of the Company by providing a funding method that aligns well with our needs and, at the same time, helps mitigate temporary impacts on our stock price. For the Scheme, we have determined the terms and conditions (including calculation methods) of all five tranches of the allotment at the initial Board of Directors meeting held on October 6, 2023, and disclosed these matters at once. Compared with five separate new share issuances, the Scheme makes it easier to visualize the entire fundraising scheme and requires less time and expenses. Based on a comprehensive assessment, we have decided to adopt the Scheme.

(3) Scheme Characteristics

The Scheme has the following advantages and disadvantages.

Advantages:

a) High probability of financing

The probability of the necessary funds being raised is relatively high. In principle, the Allottee intends to accept the shares under the Program (6,000,000 shares of common stock), and the shares will, in principle, be issued in full by April 19, 2024.

b) Limit on the maximum number of shares to be delivered

The number of common shares of the Company to be issued under the Program is fixed, at 6,000,000 shares. The number of shares to be delivered is capped, regardless of stock price fluctuations. Therefore, the dilution ratio will not be higher than initially expected.

c) Increase in funding amount if the share price rises

Under the Program, the issue price for each allocation is determined by the market price at the time of the allocation, so if the share price rises, the amount of funds raised will increase.

d) Dispersed timing of dilution

Under the Program, new shares are issued in five installments, so the timing of the issuance can be spread out, minimizing the impact on the market, rather than causing major dilution at one time.

e) Issuance timing fixed, in principle

Under the Program, in principle new shares will be issued according to the schedule disclosed today. Therefore, the timing of the issuance of new shares is more transparent than schemes under which the timing of new share issuance is uncertain, such as when using stock acquisition rights.

f) Ensures flexible capital policy

In the event that a change in capital policy becomes necessary, the Company may elect not to make an Allotment Resolution for a certain allotment by notifying the Allottee at least 11 trading days prior to the Allotment Resolution Date corresponding to that allotment.

Disadvantages:

a) Not fully funded at the outset

The Program is characterized by the fact that it raises funds in five installments, in the amount obtained by multiplying the issue price by the number of shares to be issued in each installment. Therefore, funds are not fully procured at the inception of the Program.

b) Possible decrease in funding amount

Under the Program, the issue price for each allotment is determined based on the market price at the time of the allotment. Therefore, if the stock price remains below the original issue price for a long period of time, the amount raised may be less than the amount estimated based on the original issue price. In addition, if there are reasons for limiting an allotment, such as the Company possessing insider information, the corresponding allotment may not take place, reducing the amount of funds raised.

c) Allottee's sale of common shares of the Company in the market could cause the Company's share price to decline

The Allottee's policy with respect to the common shares of the Company is to hold them for a short period of time. In principle, the Allottee intends to sell these shares on the open market, unless it finds an off-market counterparty to sell them to. Given the current level of liquidity of the common shares of the Company, the sale of the common shares of the Company by the Allottee could cause the Company's stock price to decline.

d) Limits access to unspecified new investors

As this is a third-party allotment method, which means that only the Company and the Allottee will be involved, the Company will not be able to enjoy the benefits of raising funds from an

unspecified number of new investors.

(4) Comparison with Other Funding Methods

1) Capital increase through new share issuance

(a) Capital increase through public offering

A capital increase through public offering and issuance of new shares makes one-time funding possible. However, the Company has determined that this funding method is not appropriate because it would have a large temporary and direct impact on the share price, as it simultaneously causes a dilution of earnings per share. Also, in light of the Company's current performance trends and financial condition, we believe it would be difficult to find a securities company willing to underwrite common shares of the Company, and no such proposal has actually been received from a securities company.

(b) Capital increase through shareholder allocation

A capital increase through shareholder allocation would remove the concerns about dilution. However, the Company has determined that this funding method is inappropriate because there have been few cases implemented in recent years, the participation rate of existing shareholders is uncertain, different to the Scheme it is highly unlikely that the Company could raise the necessary funds, and setting the subscription amount low in order to boost the participation rate would have an undeniably large negative impact on the share price.

(c) Capital increase through third-party allotment (single issuance)

While a third-party allotment of new shares could be an effective way for us to raise funds at one time, we believe it would be difficult to find investors willing to accept the same amount of shares as under the Scheme. We have also been unable to find such investors.

2) Moving strike convertible bonds ("MSCB," also known as convertible bonds with stock acquisition rights)

Although moving strike convertible bonds can raise funds at the time of initial issuance, initially the entire amount of the bonds is a liability, and the subsequent conversion status depends on the stock price. If the bonds are not exercised due to stock price conditions or other considerations, they remain as liabilities, which would be detrimental to the Company's financial soundness. Accordingly, the Company has determined that this is not an appropriate funding method.

3) Stock acquisition rights with a fixed exercise price

Stock acquisition rights with a fixed exercise price are less certain to raise funds than the Scheme because the Company cannot enjoy the benefits of an increase in the share price when the share price rises. At the same time, it would be difficult to raise funds when the share price falls because the rights would not be exercised. Therefore, we believe fundraising certainty of this method is lower than that of the Scheme, so we have determined that this is not an appropriate funding method.

4) Capital increase through gratis allotment of stock acquisition rights (rights issue)

Capital increases through gratis allotment of stock acquisition rights—so-called rights issues—are of two types. There are commitment-type rights issues, whereby the issuing company enters into an underwriting agreement with a financial instruments business operator, and non-commitment-type rights issues, whereby the issuing company does not enter into any such agreement and the exercise of the stock acquisition rights is entrusted to the decision of shareholders. There are few examples of commitment-type rights issues being carried out in

Japan, and at this point in time the Company does not propose to implement such an issue. Non-commitment-type rights issues are similar to a capital increase through shareholder allocation mentioned above in 1) (b) in that the participation rate of existing shareholders and the probability of fundraising are uncertain, and setting the subscription amount low in order to boost the participation rate would have an undeniably large negative impact on the share price.

5) Funding through loans or corporate bonds

Funding through loans or corporate bonds would mean that all the funds raised would be recorded as a liability, so we have determined this funding method to be inappropriate at this time.

6) MSCBs, etc.

The Scheme is economically similar to MSCBs, etc., in that the issue price of the shares is determined based on the stock price over a certain period of time. However, we could not expect MSCBs, etc. to be exercised if the share price were to fall below the minimum exercise price, and the decision to exercise MSCBs, etc., is in principle at the discretion of the allottee. Also, the timing of exercise is uncertain, whereas under the Scheme, the timing of issuance is determined in advance. Accordingly, we believe the Scheme is more appropriate at this time.

The funds raised under the Program will be used as development funds for the antiviral drug brincidofovir, and to invest in new in-licensing and M&A for the purpose of securing long-term growth opportunities as described in “II. Issuance of New Shares through Third-Party Allotment, 2. Purposes of and Reasons for the Offer.” Our objective is to bring new products to market by implementing measures swiftly, and an approach providing a high probability of financing is necessary to ensure this process is as reliable as possible. Accordingly, the Company considered various methods, focusing on the probability of fundraising.

Against this backdrop, we received a proposal from the Allottee for funding through the third-party allotment of common shares of the Company based on the Program. After considering the advantages and disadvantages of the various funding methods mentioned above, we decided to proceed with funding based on the Program. The Company has not received any specific proposals for fundraising through the issuance of common shares of the Company from any securities firm or potential investor other than the Allottee.

With regard to details of the Program, the total number of common shares of the Company to be allotted, 6,000,000 shares, was determined through frank discussions between the Allottee and the Company. Specifically, the number of shares to be allotted was based on the Company's request, taking into account potential dilution and the impact on existing shareholders, given the Company’s current stock price, and in the aim of achieving the fundraising objectives described below in “II. Issuance of New Shares through Third-Party Allotment, 3. Amount to Be Raised, and the Use and Scheduled Disbursement Thereof, (2) Specific Uses of the Amount to Be Raised.” However, as is described below in “4. Reasons for Having Chosen the Allottee, etc., (3) Allottee’s Holding Policy,” the Allottee’s policy with respect to the common shares issued through the Program is to hold them for a short period of time. The Allottee intends to sell these shares on the open market, unless it finds an off-market counterparty to sell them to. It was necessary, therefore, for the Allottee to have a number of common shares of the Company that it could hold after each allocation, that would not significantly affect the Company’s stock price, and that would allow for sale through the market without undue difficulty. Following discussions with the Allottee and taking into consideration the current liquidity of

common shares of the Company, we decided to allocate the shares in five separate tranches, as requested by the Allottee, to complete the fundraising over a period of approximately six months.

3. Overview of the Program

(1)	Target shares	Common shares of the Company
(2)	Number of target shares	Maximum of 6,000,000 shares
(3)	Issue price	The issue price for each allotment will be the amount equal to 100% of the simple average of the closing price of common shares of the Company in ordinary trading announced by the TSE during the 10 trading days up to and including the day immediately preceding the Allotment Resolution Date (rounded off to the first decimal place). (However, if there is no closing price for any of the 10 trading days, the Allottee may decide whether to include such a day in the calculation of the issue price.)
(4)	Quantity allocated	1st allotment: 1,200,000● shares 2nd allotment: 1,200,000● shares 3rd allotment: 1,200,000● shares 4th allotment: 1,200,000● shares 5th allotment: 1,200,000● shares
(5)	Allottee	EVO FUND

(Notes) If reasons for limiting allotment exist at the Allotment Resolution Date associated with an allotment, the Company will not adopt the Allotment Resolution for that allotment.
Quantities allocated for the 1st through 5th allotments are provisional, as of the date of this release. The final quantity allocated for each allotment from the 1st through 5th allotments will range from 1,200,000 shares to 2,500,000 shares, and the total will not exceed the 6,000,000 shares stipulated for issuance under the Program. Quantities will be determined by the Allottee notifying the Company prior to the Allotment Resolution Date corresponding to each allotment.

4. Reasons for Having Chosen the Allottee, etc.

(1) Outline of the Allottee

1)	Name	EVO FUND
2)	Location	c/o Intertrust Corporate Services (Cayman) Limited One Nexus Way, Camana Bay, Grand Cayman KY1-9005, Cayman Islands
3)	Grounds for foundation	Tax-exempt limited liability company based on the laws of the Cayman Islands
4)	Purpose of formation	Investment
5)	Date of formation	December 2006
6)	Total investment amount	Paid-in capital: US$1.00 Net assets: Approximately US$68 million
7)	Investors,	Voting rights: 100% Evolution Japan Group Holding Inc. (Michael

	investment ratio, and outline of investors	L. Lerch indirectly holds 100% of the voting rights to Evolution Japan Group Holding Inc.)	
8)	Position and name of representative	Representative director: Michael L. Lerch Representative Director: Richard Chisholm	
9)	Overview of Japanese agent	Name	Evolution Japan Securities Co., Ltd.
		Location	4-1 Kioicho, Chiyoda City, Tokyo
		Position and name of representative	Representative Director: Shaun Lawson
		Business	Financial instruments business
		Capital	¥994,058,875
10)	Relationship between SymBio and said fund	Relationships between SymBio and said fund	Not applicable
		Relationships between SymBio and representatives of said fund	Not applicable
		Relationships between SymBio and Japanese agent of said fund	Not applicable

(Notes) Information on the Allottee is as of July 31, 2023.

SymBio has checked past newspaper articles, the web, and other media and confirmed that no relationships with any organized crime groups exist with EVO FUND, which was introduced via Evolution Japan Securities Co., Ltd., its 100% investor and director Michael L. Lerch, or director Richard Chisholm, and confirmed that the Allottee is not an organized crime group. The Allottee has also submitted to SymBio a written pledge stating it has absolutely no relationships with any organized crime groups.

Furthermore, to ensure the utmost care, SymBio retained JP Research & Consulting, Inc. (3-7-12 Toranomon, Minato-ku, Tokyo, Japan; President and CEO: Keisuke Furuno), a third-party research institute specialized in a variety of research, including company and credit research, to conduct research on EVO FUND, its 100% investor and director Michael L. Lerch, and director Richard Chisholm. As a result of this research, including collation with databases that JP Research & Consulting possesses, SymBio received reports indicating that the Allottee, its investors, and executives are not involved with any organized crime groups.

SymBio's comprehensive judgment based on the above is that neither the Allottee nor its investors or executives are involved with any organized crime groups. Accordingly, the Company has submitted to the TSE a note of confirmation of non-involvement with any organized crime groups.

(2) Reason for Having Chosen the Allottee

SymBio has carefully considered multiple funding methods in the aim of expeditiously and reliably enhancing its corporate value and developing its business. In this context, Evolution Japan Securities Co., Ltd., an affiliate of the Allottee, initially proposed the Scheme for fundraising in July 2023. After internal discussions and evaluations, we determined that the Scheme aligns with our financing needs, as it offers a high probability of raising the necessary funds for our future business operations, while also mitigating temporary impacts on our stock price. After internal discussions and consideration, we have also determined that the Allottee is suitable, based on past investment performance. As a result, we have decided to adopt the Scheme and make EVO FUND the Allottee. In the purchase agreement

with CVI Investments, Inc. entered into on May 16, 2022, the Company agreed to a lock-up provision, but has determined that the Capital Increase by Third-Party Allotment is not subject to the said provision. For details of the lock-up provision, please see the “Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment” released May 16, 2022 (the “Press Release on the Previous Capital Increase”).

The Allottee is a fund (a tax-exempt limited liability company based on the laws of the Cayman Islands) established in December 2006 for the purpose of investing in listed companies.

The Allottee’s affiliated company, Evolution Japan Securities Co., Ltd., was in charge of arranging this funding, as part of its mediation business for the purchase by its affiliated company. Evolution Japan Securities Co., Ltd. is a wholly owned subsidiary of British Virgin Islands-based Tiger Inn Enterprises Limited (Craigmuir Chambers, PO Box 71, Road Town, Tortola VG1110, British Virgin Islands; Representative directors: Michael L. Lerch and Richard Chisholm).

(Note) The allotment of the Shares, intermediated through Evolution Japan Securities Co., Ltd., a member of the Japan Securities Dealers Association, shall go to the Allottee, and are offered in accordance with the Japan Securities Dealers Association’s “Rules Concerning Handling of Allotment of New Shares to Third Party, etc.” (self-regulatory rules).

(3) Allottee’s Holding Policy

The objective of the Allottee is pure investment, and in principle the Allottee’s intention is not to hold for a long period common shares of the Company it acquires. We have verbally confirmed the Allottee’s intention to sell the Shares in response to market trends and to abstain from transactions that will make uncertain the true number of shares it holds (for instance, engaging in swap transactions with institutional investors or financial institutions during the period of the Program). Furthermore, we plan to obtain a written confirmation from the Allottee stating its agreement to promptly report to us in writing if it transfers all or a portion of the Shares within two years from the issuance date. We will also report the contents of such report to the TSE and obtain the Allottee's agreement that the reported contents will be made available for public viewing.

In connection with the issuance of the Shares, the Allottee may enter into a stock lending agreement with Fuminori Yoshida, who is both a major shareholder of the Company and its representative director, president, and chief executive officer (contract period: October 6, 2003 to May 2, 2024, number of shares for lending: 1,179,700 shares, lending fee: 0% per annum, collateral: none), borrowing common shares of the Company that it may sell for the purpose of hedging.

The Allottee will not borrow common shares of the Company for the purpose of engaging in any short-selling activities, except for selling for hedging purposes within the quantity of common shares of the Company issued through each allotment. The agreement between SymBio and the Allottee stipulates that the Allottee shall not engage in the short-selling of borrowed common shares of the Company other than selling for hedging purposes within the quantity of common shares of the Company issued through each allotment.

II. Issuance of New Shares through Third-Party Allotment

1. Summary of Offer

The Program involves issuance of the Shares in a series of third-party allotments (1st through 5th allotments), as described above in “I. STraight-Equity Issue Program (“STEP”), 1. Details of the Program” and based on the Agreement to Set up an Equity Issue Program. Overviews of the 1st through 5th

allotments are provided below.

(1) 1st allotment

(1)	Allotment Resolution Date	October 25, 2023
(2)	Due date of payment	November 10, 2023
(3)	Number of new shares to be issued	1,200,000 common shares
(4)	Issue price	To be determined
(5)	Amount of funding	To be determined
(6)	Offer method	Third-party allotment
(7)	Allottee	EVO FUND
(8)	Others	Each of the above items is subject to the effectiveness of the filing under the Financial Instruments and Exchange Act. After the filing under the Financial Instruments and Exchange Act becomes effective, the Company intends to enter into a third-party allotment agreement with EVO FUND to subscribe for the new shares to be issued through the allotment.

(Notes) 1. Regarding the Allotment Resolution Date for the 1st allotment, if there are reasons for limiting allotment, the Company will not adopt the Allotment Resolution for the 1st allotment and will at that point withdraw the securities registration statement for the 1st allotment.

2. The Allotment Resolution Date and the due date of payment may be changed, if agreed upon by the Company and the Allottee. If such changes occur, the Company will withdraw the securities registration statement for the 1st allotment and submit a new securities registration statement.

3. In accordance with the terms of the Program, the issue price is expected to be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the TSE during the 10 trading days up to and including the day preceding October 25, 2023 (rounded off to the first decimal place).

4. The number of new shares to be issued is the provisional quantity to be allocated as of the date of this release. The final quantity allocated shall be in the range from 1,200,000 shares to 2,500,000 shares. The quantity shall be determined by the Allottee notifying the Company prior to the Allotment Resolution Date.

(2) 2nd allotment

(1)	Allotment Resolution Date	December 4, 2023
(2)	Due date of payment	December 20, 2023
(3)	Number of new shares to be issued	1,200,000 common shares
(4)	Issue price	To be determined
(5)	Amount of funding	To be determined
(6)	Offer method	Third-party allotment
(7)	Allottee	EVO FUND

(8)	Others	Each of the above items is subject to the effectiveness of the filing under the Financial Instruments and Exchange Act. After the filing under the Financial Instruments and Exchange Act becomes effective, the Company intends to enter into a third-party allotment agreement with EVO FUND to subscribe for the new shares to be issued through the allotment.

(Notes) 1. Regarding the Allotment Resolution Date for the 2nd allotment, if there are reasons for limiting allotment, the Company will not adopt the Allotment Resolution for the 2nd allotment and will at that point withdraw the securities registration statement for the 2nd allotment.

2. The Allotment Resolution Date and the due date of payment may be changed, if agreed upon by the Company and the Allottee. If such changes occur, the Company will withdraw the securities registration statement for the 2nd allotment and submit a new securities registration statement.

3. In accordance with the terms of the Program, the issue price is expected to be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the TSE during the 10 trading days up to and including the day preceding December 4, 2023 (rounded off to the first decimal place).

4. The number of new shares to be issued is the provisional quantity to be allocated as of the date of this release. The final quantity allocated shall be in the range from 1,200,000 shares to 2,500,000 shares. The quantity shall be determined by the Allottee notifying the Company prior to the Allotment Resolution Date.

(3) 3rd allotment

(1)	Allotment Resolution Date	January 22, 2024
(2)	Due Date of payment	February 7, 2024
(3)	Number of new shares to be issued	1,200,000 common shares
(4)	Issue price	To be determined
(5)	Amount of funding	To be determined
(6)	Offer method	Third-party allotment
(7)	Allottee	EVO FUND
(8)	Others	The allotment is subject to the effectiveness of the filing under the Financial Instruments and Exchange Act. After the filing under the Financial Instruments and Exchange Act becomes effective, the Company intends to enter into a third-party allotment agreement with EVO FUND to subscribe for the new shares to be issued through the allotment.

(Notes) 1. Regarding the Allotment Resolution Date for the 3rd allotment, if there are reasons for limiting allotment, the Company will not adopt the Allotment Resolution for the 3rd allotment and will at that point withdraw the securities registration statement for the 3rd allotment.

2. The Allotment Resolution Date and the due date of payment may be changed, if agreed upon by the Company and the Allottee. If such changes occur, the Company will withdraw the securities registration statement for the 3rd allotment and submit a new securities registration statement.

3. In accordance with the terms of the Program, the issue price is expected to be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the TSE during the 10 trading days up to and including the day preceding January 22, 2023 (rounded off to the first decimal place).
4. The number of new shares to be issued is the provisional quantity to be allocated as of the date of this release. The final quantity allocated shall be in the range from 1,200,000 shares to 2,500,000 shares, and the total number of shares issued under the Program shall not exceed 6,000,000 shares. The quantity shall be determined by the Allottee notifying the Company prior to the Allotment Resolution Date.

(4) 4th allotment

(1)	Allotment Resolution Date	February 29, 2024
(2)	Due Date of payment	March 18, 2024
(3)	Number of new shares to be issued	1,200,000 common shares
(4)	Issue price	To be determined
(5)	Amount of funding	To be determined
(6)	Offer method	Third-party allotment
(7)	Allottee	EVO FUND
(8)	Others	The allotment is subject to the effectiveness of the filing under the Financial Instruments and Exchange Act. After the filing under the Financial Instruments and Exchange Act becomes effective, the Company intends to enter into a third-party allotment agreement with EVO FUND to subscribe for the new shares to be issued through the allotment.

(Notes) 1. Regarding the Allotment Resolution Date for the 4th allotment, if there are reasons for limiting allotment, the Company will not adopt the Allotment Resolution for the 4th allotment and will at that point withdraw the securities registration statement for the 4th allotment.
2. The Allotment Resolution Date and the due date of payment may be changed, if agreed upon by the Company and the Allottee. If such changes occur, the Company will withdraw the securities registration statement for the 4th allotment and submit a new securities registration statement.
3. In accordance with the terms of the Program, the issue price is expected to be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the TSE during the 10 trading days up to and including the day preceding February 29, 2024 (rounded off to the first decimal place).
4. The number of new shares to be issued is the provisional quantity to be allocated as of the date of this release. The final quantity allocated shall be in the range from 1,200,000 shares to 2,500,000 shares, and the total number of shares issued under the Program shall not exceed 6,000,000 shares. The quantity shall be determined by the Allottee notifying the Company prior to the Allotment Resolution Date.

(5) 5th allotment

(1)	Allotment Resolution Date	April 3, 2024
(2)	Due Date of payment	April 19, 2024

(3)	Number of new shares to be	1,200,000 common shares
(4)	Issue price	To be determined
(5)	Amount of funding	To be determined
(6)	Offer method	Third-party allotment
(7)	Allottee	EVO FUND
(8)	Others	The allotment is subject to the effectiveness of the filing under the Financial Instruments and Exchange Act. After the filing under the Financial Instruments and Exchange Act becomes effective, the Company intends to enter into a third-party allotment agreement with EVO FUND to subscribe for the new shares to be issued through the allotment.

(Notes) 1. Regarding the Allotment Resolution Date for the 5th allotment, if there are reasons for limiting allotment, the Company will not adopt the Allotment Resolution for the 5th allotment and will at that point withdraw the securities registration statement for the 5th allotment.

2. The Allotment Resolution Date and the due date of payment may be changed, if agreed upon by the Company and the Allottee. If such changes occur, the Company will withdraw the securities registration statement for the 5th allotment and submit a new securities registration statement.

3. In accordance with the terms of the Program, the issue price is expected to be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the TSE during the 10 trading days up to and including the day preceding April 3, 2024 (rounded off to the first decimal place).

4. The number of new shares to be issued is the provisional quantity to be allocated as of the date of this release. The final quantity allocated shall be in the range from 1,200,000 shares to 2,500,000 shares, and the total number of shares issued under the Program shall not exceed 6,000,000 shares. The quantity shall be determined by the Allottee notifying the Company prior to the Allotment Resolution Date.

2. Purposes of and Reasons for the Offer

SymBio has explored various funding methods to raise the funds described in “Purpose of the Funding” below. The Company’s reasons for selecting the funding method used for the Program are described in “I. STraight-Equity Issue Program (“STEP”), 2. Reasons, etc., for Introducing the Program, (2) Reason for Selecting the Program as a Funding Method,” and the Company has decided that the Scheme best fits its funding needs. Accordingly, the Company will pursue funding through the Capital Increase by Third-Party Allotment.

[Purpose of the Funding]

SymBio is a pharmaceutical company established in March 2005 by Fuminori Yoshida, who previously served concurrently as Corporate VP of Amgen Inc. (U.S.) (Note 1) and President of Amgen K.K., a wholly owned subsidiary of Amgen Inc., (now part of Takeda Pharmaceutical Company Limited) for roughly 12 years since its establishment.

The Company aims to achieve its social and management responsibilities by responding to unmet medical needs (Note 2) based on the guiding principle of mutual harmony, creating an intricate symbiotic relationship between patients, physicians, scientists, regulators, and investors.

(Note 1) Applied Molecular Genetics Inc. (“Amgen”), the world’s largest company in the biopharmaceutical field, was founded in Thousand Oaks, California, in 1980, and started operating in Japan as Amgen K.K. in May 1993. After Takeda Pharmaceutical Company Limited acquired all of Amgen K.K.’s shares in February 2008, its operations were merged into Takeda Pharmaceutical.

(Note 2) “Unmet medical needs” refer to the needs for medical treatment that have not yet been fulfilled. The term refers to situations in which no effective drugs or treatments are currently available, despite strong demand by patients and/or physicians.

Much of the research and development into orphan drugs to treat rare diseases (Note 3) in the areas of oncology and hematology is conducted not by major pharmaceutical companies but rather by a large number of universities, research institutions, and biotech startup companies mainly in Europe and the U.S., which actively engage in drug discovery research and new drug development, and already provide numerous useful new drugs to medical sites overseas. However, development in these fields is complex and therefore requires a high degree of specialization, making it difficult for major pharmaceutical companies to embark on such development from a business efficiency and profitability standpoint. As a result, these fields remain untapped not only in Japan but in many countries around the world. SymBio regards underserved therapeutic areas with extremely significant medical needs as business opportunities, and it concentrates particularly on the areas of oncology and hematology, where high barriers to entry exist due to the high degree of specialization required. In this sense, it is the first specialty pharmaceutical company (Note 4) in Japan. Rather than exploring opportunities to in-license and develop new “blockbuster” drugs (drugs with sales exceeding ¥100 billion), the Company channels its resources into the development of drugs for underserved markets where medical needs are high despite limited patient numbers. Holding multiple drug approvals and new drug candidates in these key therapeutic areas, the Company has built a solid pipeline portfolio with the aim of achieving high profitability with high-value products and services and operating sustainable businesses.

SymBio was founded with the corporate mission of developing and supplying new drugs to serve these types of underserved markets. It regards short-term development of drugs for patients who face treatment problems due to the lack of development of new drugs, and the rapid delivery of therapeutic drugs as its top priority, and it aims to concurrently fulfill its corporate mission and achieve sustainable growth as a company by contributing to medicine and the healthy development of the pharmaceutical industry.

(Note 3) The rare-disease field is one in which the number of patients requiring drugs is small. Drugs for this field are called “orphan drugs.” The Japanese Ministry of Health, Labour and Welfare (MHLW) has established an orphan drug designation system for drugs meeting criteria such as treating a serious disease that affects less than 50,000 people in Japan, and being highly necessary as a medical treatment. Once the designation is obtained, a drug enjoys various advantages including expediting the time from regulatory submission for review of the drug to approval, and the extension of the re-examination period for up to 10 years.

(Note 4) A specialty pharmaceutical company is a company that develops new drugs and has earned a certain degree of recognition, including internationally, for its research and development capabilities in a specialized field (according to the definition included in the “2007 Pharmaceutical Industry Vision” of the MHLW).

Two well-known characteristics of the drug discovery business are that the development of new drugs requires massive amounts of investment over a long period of time, and that probability for success in research and development is extremely low. It is said that, as a general rule, the probability of a compound that is deemed to have some type of biological or physiological activity (Note 5) in a research laboratory being approved as a new drug is only one in 20,000 to 25,000 (source: “Pharmaceutical Industry Textbook 2020–2021,” Japan Pharmaceutical Manufacturers Association). Further, it has become increasingly difficult to maintain the profitability of approved drugs over the long term, in large part because drug prices are now revised down annually following a major overhaul in the Japanese drug price system in 2018. SymBio has developed a business model that takes into account these challenges of the drug discovery business.

To reduce the various risks and costs associated with development, rapidly and reliably advance clinical trials for new drug candidates, and accordingly expedite the period from the start of development to approval of the new drug, the Company mainly targets compounds for which a proof of concept (POC) (Note 6) has already been established in human subjects, and for which preclinical and clinical trial data are available. It uses its proprietary search network and evaluation process to identify new compounds, which are first screened in-house by a team of specialized staff with extensive internal experience. Thereafter, its Scientific Advisory Board (SAB) (Note 7) determines the final in-licensing candidate after rigorous evaluation by external experts who possess a wealth of experience at the forefront of therapeutic research in related fields.

Through this rigorous selection process conducted by internal and external experts, SymBio continually secures rights to develop, manufacture, and market drugs—chiefly drugs in the areas of oncology and hematology for which a POC has been established in human subjects, developed by pharmaceutical companies, biotech startup companies, and other parties—around the world, particularly in Japan, Asian countries, Europe, and the U.S., and accordingly operates a sustainable business. In addition to the aforementioned selection process, a key factor in being able to in-license commercially viable and attractive drug candidates with a high probability of success has been gaining a favorable reputation among licensers, which provide the drug candidates under development, by virtue of development capabilities in highly complex therapeutic fields such as oncology and hematology. Such a reputation hinges on (1) the formulation of appropriate clinical trial protocols, (2) the selection of appropriate clinical trial subjects for the treatment under development, and (3) the presence of competent development staff with a high degree of specialization who can build and maintain fair relationships with medical professionals in the relevant areas. The combination of these three factors has powered the Company’s development capabilities, facilitating steady yet rapid development. In the case of the anticancer agent SyB L-0501, the Company deployed a development team mainly composed of human resources who have experience working at development units of major pharmaceutical companies with a track record in the areas of oncology and hematology. The team managed to complete the process from in-licensing to approval filing in only four years, from 2005 to 2009. This achievement not only earned the Company high praise from licensers, partners, and companies that develop in-licensing drug candidates, but also contributed to a subsequent increase in the number of in-licensing candidates being considered by the Company and multiple in-licensed drugs being added to the Company’s product pipeline.

On the development front, SymBio mainly handles tasks that are central to its fundamental development strategy such as design of clinical trials, cooperation with overseas studies, and coordination with medical professionals. It outsources routine development work to a contract research

organization (CRO) (Note 8), relying on external resources, and manufacturing work to the original licensor or pharmaceutical companies in Japan or overseas deemed trustworthy by the Company.

In terms of sales, SymBio had sold its products in Japan through Eisai Co., Ltd. under a business partnership agreement concluded in August 2008. However, as this agreement was set to expire in December 2020, the Company began preparations to build its own salesforce for domestic sales of TREAKISYM® (Note 9) from October 2018. Specifically, the Company formed a nationwide salesforce composed of medical representatives (MRs) (Note 10) with extensive expertise in the areas of oncology and hematology, pushed ahead with the development of distribution and logistics functions, formulated marketing strategies and plans, and worked to strengthen its marketing systems used to conduct market surveys. Through such initiatives, it cultivated favorable relationships with key opinion leaders (KOL) (Note 11) in the relevant therapeutic fields, ascertained precise medical needs, conducted market research, prepared systems to captures various data and expertise, and ultimately transitioned to its own salesforce upon the expiration of the aforementioned agreement in December 2020 as scheduled.

(Note 5) Physiological activity is the property of chemical substances having an effect on specific physiological, regulatory functions of the body. Physiologically active chemical substances can be applied in treatments for rare diseases, in which case they become pharmaceuticals.

(Note 6) Proof of concept (POC) means confirming the efficacy and safety of a new drug candidate in clinical trials and verifying its practical potential.

(Note 7) The Scientific Advisory Board (SAB) of SymBio creates a product portfolio with a balanced risk–return trade-off selected from a vast number of drug candidates from around the world, and formulates the pipeline strategy by exchanging opinions and proposals and engaging in thorough discussion from different professional standpoints about factors such as the degree of medical demand and profitability. As such, it is an essential evaluation body of the Company. The SAB convenes two to three times per year, and is attended by highly experienced clinicians and fundamental scientists with an excellent track record from around the world, who serve as advisors on drug discovery research and new drug development to the Company.

(Note 8) A contract research organization (CRO) is an organization that undertakes certain operations under contract for pharmaceutical companies, thus supporting the latter in their efforts to conduct development activities without delay. The details of the commissioned activities may include monitoring to ensure that clinical trials are carried out in accordance with clinical trial protocols and clinical data management.

(Note 9) TREAKISYM® (development code: SyB L-0501, generic name: bendamustine hydrochloride or bendamustine hydrochloride hydrate)

(Note 10) Medical representatives (MRs) possess expert knowledge about the pharmaceutical products supplied by the Company, and mainly provide, collect, and disseminate information regarding the quality, efficacy, safety, and other aspects of such products when visiting medical institutions and holding meetings with medical professionals.

(Note 11) Key opinion leaders are physicians who wield influence over peers in their therapeutic field.

To achieve success in the aforementioned operations, SymBio mainly pursues the following five business strategies.

(a) Reducing development risk through post-POC strategy

As a rule, the drug candidates in-licensed by SymBio (Note 12) are mainly drug candidates for which a POC has already been established in human subjects. Consequently, the Company targets drug candidates that are in a relatively late stage of clinical development or are already on the market overseas. It is able to mitigate development risk by using in-licensed drug candidates that have already undergone development overseas and have been confirmed to be effective and safe as a new drug in human subjects. It uses existing clinical data available overseas to expedite development timelines, reduce development costs, and increase the likelihood of securing regulatory approvals in Japan and other countries around the world.

(Note 12) In-licensed drug candidates are compounds developed by other companies for which SymBio considers acquiring development and other rights as a development candidate.

(b) Building a high-quality pipeline with exceptional search and evaluation capabilities

SymBio's drug search engine is connected to a diverse network of pharmaceutical and bio venture companies, enabling it to select promising drug candidates from a vast number of chemical compounds based on careful review by internal experts. The final in-licensing candidates are carefully evaluated by Scientific Advisory Board (SAB) members with a wealth of experience at the forefront of research, and determined based on their advice and assessment. This advanced screening process up to the final selection of drug candidates, coupled with the post-POC strategy (which involves in-licensing drug candidates whose efficacy and safety have already been confirmed overseas), reduces development risk and expedites development timelines. It also helps the Company understand whether the drug candidates could meet healthcare needs (i.e., whether they are needed in medical settings), and improves the accuracy of earnings projections after a product launch.

(c) Controlling fixed costs through labless/fabless strategy (Note 13)

SymBio does not operate any proprietary research or manufacturing facilities, which are a major source of fixed costs. In the absence of such facilities, once drug candidates are searched and in-licensed, the Company focuses on value-added activities such as the formulation and implementation of development strategies, and outsources other necessary routine procedures. This enables the Company to reduce drug development costs while maintaining a flexible financial strategy.

(Note 13) A labless/fabless strategy allows SymBio to avoid the risks of procuring and holding research facilities, production facilities, and human resources, and channel or concentrate its limited management resources into value-added areas such as planning, development, design, and marketing.

(d) Achieving high business efficiency through "blue ocean" strategy (Note 14)

Many standard drugs used overseas cannot be prescribed in Japan, and it is not uncommon for a new drug to be launched in Japan nearly five years behind its initial approval overseas. Referred to as "drug lag," this problem continues to intensify and has led to the term "cancer patient refugee" being coined. The drug lag is particularly conspicuous in SymBio's strategic drug development areas of

refractory cancer and hematological diseases. Japan constitutes a large market for anticancer agents that continues to expand with the aging population. However, because anticancer agents have a wide range of indications and are broken up by the type of tumor, many therapeutic areas only have a limited number of patients. Developing new agents in these therapeutic areas is difficult and requires an extremely high degree of specialization, making these areas often financially unattractive for larger pharmaceutical companies to pursue. This is said to be part of the cause of the delay in drugs coming to market. On the other hand, SymBio believes that obtaining approval and launching a new drug in one of these less competitive therapeutic areas creates an opportunity to achieve further growth and profitability by continuously expanding indications and bringing new products to the market.

(Note 14) A “blue ocean” strategy means a strategy of redefining the market, avoiding marketplaces with fierce competition in which rivals seeks to gain limited market share (referred to as “red oceans”), and instead creating an unexploited market with reduced competition (referred to as “blue oceans”) in an effort to maximize profits while providing high-value products and services to customers.

(e) Going global beyond Asia

To date, SymBio has mainly operated its businesses in Japan and other countries in Asia. However, amid a major transformation in the business environment of the Japanese healthcare industry, the Company cannot hope to evolve substantially if its operations remain confined to Asia. For this reason, the Company searches for and evaluate new drug candidates with an eye toward global development. In September 2019, the Company concluded an exclusive global licensing agreement for antiviral drug brincidofovir (“BCV”) with Chimerix Inc. (head office: North Carolina). Under this agreement, the Company acquired the exclusive rights for the worldwide development, marketing, and manufacture of BCV for all human indications, excluding smallpox.

In March 2021, the Company filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to start a Phase II clinical trial primarily in pediatric patients (including adults) suffering from adenovirus (AdV) infections after hematopoietic stem cell transplantation. In April 2021, the FDA granted the development program a fast-track designation. In August 2021, the investigational drug was administered to the first patient enrolled in the study (first patient in or FPI). Further, in January 2022, the Company filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) of the U.K.

Based on the efficacy and safety findings from clinical trials targeting AdV infections, the Company plans to investigate the efficacy of BCV against a range of double-stranded DNA (dsDNA) viral infections (Note 15) after hematopoietic stem cell transplantation, and expand target indications to include multiple viral infections. It also plans to explore the possibility of expanding target areas to viral infections associated with kidney and other organ transplants, cancer, or other treatments. In doing so, it aims to expand the market for BCV and maximize the drug’s business value.

(Note 15) Double-stranded DNA (dsDNA) viruses include adenoviridae, polyomaviridae, papillomaviridae, poxviridae families of viruses, such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), herpes virus (HV), BK virus (BKV), papillomavirus, and smallpox virus

[Progress with SymBio Group's Development Pipeline]

The SymBio Group currently has the following pipeline products under development: SyB L-0501, SyB L-1101, SyB C-1101, SyB L-1701, SyB L-1702, and SyB V-1901. It will continue to in-license candidate drugs to further expand and build its pipeline portfolio with a balanced risk–return trade-off.

Pipeline	Indication(s)	Clinical Trial			NDA*1	MA*2
		Phase 1	Phase 2	Phase 3		
SyB L-0501 Anti-cancer agent	r/r Low-grade NHL/MCL	Approved October, 2010				
	CLL	Approved August, 2016				
	1st line Low-grade NHL/MCL	Approved December, 2016				
	r/r DLBCL	Approved March, 2021				
SyB L-1701 (RTD)※	All except for r/r DLBCL	Approved September, 2020				
	r/r DLBCL	Approved April, 2021				
SyB L-1702 (RI)※	All	Approved February, 2022				
Pipeline	Indication(s)	Clinical Trial			NDA*1	MA*2
		Phase 1	Phase 2	Phase 3		
SyB V-1901 Antivairal Drug (IV)	Adenoviral disease of immunocompromised patients including post hematopoietic stem cell transplantation			Phase II study on going		
	BKV infection post kidney Transplantation			Phase II study on going		
	CMV infection post hematopoietic stem cell transplantation	Phase Ib study on preparation				
	EB virus-related diseases Multiple Sclerosis	Preclinical study on going				
	HSV-1 Alzheimer's disease	Preclinical study on going				
	CMV infection GBM	Preclinical study on going				
Pipeline	Indication(s)	Clinical Trial			NDA*1	MA*2
		Phase 1	Phase 2	Phase 3		
SyB L-1101 Anti-cancer agent (IV)	Relapse / refractory high risk MDS monotherapy	Global phase III study completed				
SyB C-1101 Anti-cancer agent (oral)	Relapse / refractory high risk MDS 1st line high risk MDS Combination with AZA	Japan study completed		Japan study completed		
		Global phase I/II study completed		Global phase I/II study completed		

*1 NDA: New Drug Apprication
*2 MA: Marketing Approval

(1) [Anticancer agents: SyB L-0501 (FD formulation), SyB L-1701 (RTD formulation), SyB L-1702 (RI injection), (generic name: bendamustine hydrochloride or bendamustine hydrochloride hydrate, trade name: TREAKISYM®)]

Bendamustine hydrochloride (the generic name), the active pharmaceutical ingredient of SyB L-0501, is an anticancer agent that has been in use for a number of years in Germany under the trade name of Ribomustin® for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. The Company decided to in-license this product because there is currently no effective medication for the indications of recurrent/refractory low-grade non-Hodgkin's lymphoma and mantle cell lymphoma. These are underserved therapeutic areas aligned with the Company's corporate mission and also fall within one of SymBio's targeted therapeutic fields (hematologic

cancer).

In July 2018, the use of TREAKISYM® in combination with rituximab (BR therapy) was newly added to the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues issued by the Japan Society of Hematology, and became recommended as a standard treatment for all previously approved indications (relapsed or refractory low-grade Non-Hodgkin's lymphoma [NHL], mantle cell lymphoma [MCL], first-line treatment of low-grade NHL and MCL, and chronic lymphocytic leukemia [CLL]). Accordingly, TREAKISYM® has been positioned as a standard treatment for malignant lymphoma both in name and substance.

In addition to the already-approved indications, SymBio has conducted a Phase III clinical trial for TREAKISYM® targeting recurrent/refractory diffuse large B-cell lymphoma (r/r DLBCL). Based on a favorable response rate that exceeded expected levels, the primary endpoint of the study, the Company filed an application for a partial change to its manufacturing and marketing authorization in May 2020, and received the approval in March 2021.

In September 2017, SymBio entered into an exclusive license agreement with Eagle Pharmaceuticals, Inc. (head office: New Jersey, U.S.) to develop and commercialize TREAKISYM® liquid formulations (ready-to-dilute [RTD] formulation and rapid infusion [RI] injection [Note 17]) in Japan. It received approval to manufacture and market the RTD formulation in September 2020, and launched the drug in January 2021. After the clinical trial to confirm the safety of the RI injection had been completed, the Company filed for a partial change to its manufacturing and marketing authorization, and received the approval in February 2022.

Compared to the conventional freeze-dried (FD) formulation, the RTD formulation does not require complicated manual dissolution procedures, thus reducing the time required for such procedures and considerably reducing the burden on healthcare providers. The RI injection further adds value by substantially reducing the administration time compared to the one hour required for the conventional FD and RTD formulations, thereby significantly reducing the burden on both patients and healthcare providers.

(Note 16) Non-Hodgkin's lymphoma (NHL) refers to malignant lymphoma other than Hodgkin's lymphoma. Malignant lymphoma is a cancer of the lymphatic system in which lymphocytes develop malignant growths. The majority of Japanese malignant lymphoma patients are suffering from NHL.

(Note 17) Ready-to-dilute (RTD) and rapid infusion (RI) are pre-dissolved liquid formulations that differ from the conventional freeze-dried (FD) formulation. The RTD formulation significantly reduces the preparation time and the RI injection substantially reduces infusion duration from the one hour required previously, thus substantially reducing the burden on the patient and providing significant added value to healthcare professionals compared to the FD formulation.

(2) [Anticancer agents: SyB L-1101 (intravenous formulation) and SyB C-1101 (oral formulation) (generic name: rigosertib sodium)]

U.S. licensor Onconova Therapeutics, Inc. (head office: Pennsylvania, U.S.) has conducted global Phase III clinical trials (INSPIRE study) of the intravenous formulation of rigosertib for higher-risk myelodysplastic syndromes (HR-MDS) which failed to respond to the current standard treatment with hypomethylating agents, relapsed after treatment under the current standard of care, or were intolerant to hypomethylating agents; the primary endpoint of the study is overall survival. In August

2020, Onconova announced that the primary endpoint—improved survival compared to physician's choice of treatment—was not met. The Company is responsible for clinical development in Japan, and is reviewing ways to use the findings from the additional analysis of the INSPIRE study in the future development of rigosertib.

(3) [Antiviral drug: SyB V-1901 (generic name: brincidofovir)]

In September 30, 2019, the Company concluded an exclusive global licensing agreement for the intravenous and oral formulations of antiviral drug brincidofovir (SyB V-1901; "IV BCV" and "Oral BCV") with Chimerix Inc. Under this agreement, the Company acquired the exclusive rights for the worldwide development, marketing, and manufacture of BCV for all indications, excluding smallpox.

The Company has decided to prioritize the global development of the intravenous formulation of IV BCV primarily in Japan, the U.S., and Europe, targeting adenovirus (AdV) infections occurring after hematopoietic stem cell transplantation—a niche area with a high unmet medical need. In March 2021, the Company filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to conduct a Phase II clinical trial primarily in pediatric patients suffering from adenovirus (AdV) infections (also including adults). This development program was granted fast-track designation by the FDA in April 2021. In May 2023, the same study demonstrated proof of concept (POC) for BCV in human patients. As of end-June 2023, a total of 27 patients have been enrolled and patient enrollment is ongoing. BK virus (BKV) nephropathy after kidney transplantation is considered a disease with serious consequences for the recipient, the donor, the medical practitioner, and society, as it may result in serious conditions such as decreased renal function and graft loss. In order to find an early solution to this problem, SymBio submitted a clinical trial notification for a Phase II study in patients infected with BK virus after receiving kidney transplant to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in May 2022 and to the Therapeutic Goods Administration (TGA) of Australia in August 2022. The investigational drug was administered to the first patient in Australia in August 2022. The trial was originally planned to conclude in 2025, but progress has been slower than expected due to delays in patient enrollment. SymBio is considering amending the research protocol once again with the research team.

In clinical studies conducted by Chimerix in Europe and the U.S., Oral BCV has been shown to demonstrate strong antiviral activity against a broad range of viruses. Oral BCV's antiviral activity against a range of dsDNA viruses suggests that IV BCV may also be safe and effective in the prevention and treatment of various viral infections following hematopoietic stem cell transplantation.

As noted in the Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated) released on February 10, 2022 (the "Summary of Financial Statements Dated February 10, 2022"), SymBio achieved profitability—its top management priority—during the year, recording net sales of ¥8,256 million and profit of ¥2,032 million. Its cash and deposits stood at ¥3,860 million as of the end of December 2021. Further, the Company forecasts net sales of ¥10,992 million and profit of ¥1,480 million in FY 2022. In addition, as notified in its Summary of Financial Statements for the Fiscal Year Ended December 31, 2022 [Japanese GAAP] (Consolidated) released on February 9, 2023, the Company continued to operate in the black, recording net sales of ¥10,008 million and profit of ¥1,179 million. Its cash and deposits stood at ¥6,282 million as of the end of December 2022.

The Company achieved profitability—its top management priority—during the year. It has positioned

the period from 2022 as “a second stage of growth,” and formulated the following key management strategies to realize its medium- to long-term goal of evolving into a true global specialty pharmaceutical company: (1) launch the next product after TREAKISYM® by promoting development of brincidofovir (BCV), (2) take business global through full-scale operation of SymBio Pharma USA, Inc. (SPU), (3) expand and enhance product portfolio by establishing a business strategy division, and (4) develop new treatments by promoting joint research with academic institutions in Japan and overseas.

(1) In an effort to launch the next products to follow TREAKISYM® through further development of brincidofovir, SymBio has started clinical trials or is making preparations for such studies targeting four indications or therapeutic areas. One such initiative is a Phase II clinical trial targeting AdV infections, including those occurring after hematopoietic stem cell transplantation, in pediatric patients (including adults). The investigational drug was administered to the first patient enrolled (first patient in or FPI) in the U.S. in August 2021. The Company is also preparing for clinical development targeting post-hematopoietic stem cell transplant cytomegalovirus infection. Separately, it is considering development targeting Epstein-Barr (EB) virus-related diseases such as difficult-to-treat multiple sclerosis, as well as post-COVID-19 conditions assumed to be associated with EB virus, and taking related steps. In addition to strong antiviral effects, brincidofovir is expected to have antitumor effects. Through joint research with the National Cancer Centre Singapore and the Brain Tumor Center of the Department of Neurological Surgery at the University of California, San Francisco (UCSF), the Company is investigating new indications for brincidofovir in oncology, including rare brain tumors and Epstein-Barr (EB) virus-positive lymphoma.

(2) In preparation for the globalization of business through the full-fledged operation at SymBio Pharma USA, Inc., in August 2023 Stephane Berthier, PharmD was appointed president and CEO of SymBio Pharma USA. In September 2023, Nkechi Azie, MD joined the management team, assuming the position of global chief medical officer (CMO). In these ways, SymBio is significantly expanding its global development structure and advancing the global development plan for BCV, with SymBio Pharma USA as the driving force for international clinical trials.

(3) With a view to expanding its product portfolio through the establishment of a business strategy division, SymBio will push ahead with the global development of brincidofovir and promote global partnerships to facilitate commercialization, continue to review multiple licensing deals, and aim to generate medium- to long-term business value as a profitable biopharmaceutical company with growth potential by searching and evaluating new drug candidates for potential in-licensing.

(4) In the development of new treatments through the promotion of joint research with academic institutions in Japan and overseas, in addition to the joint research for brincidofovir mentioned above, SymBio is actively conducting further research on TREAKISYM®, such as joint research with Kyoto University, to explore new possibilities of the drug. In addition, with regard to TREAKISYM® and rigosertib, the Company is conducting joint research with the University of Tokyo and other parties to investigate new effects of the drugs used in combination with each other as well as with other existing drugs, and to look for new indications.

To achieve these strategies, SymBio will use the earnings from TREAKISYM® to cover SG&A expenses (mainly comprising sales and personnel expenses), and need to select timely and appropriate means to build strategic partnerships and raise long-term funding for investment in research and development, which will require substantial expenditures over the long term. However, the recent external environment surrounding the Company has been affected by factors such as widespread uncertainty in the financial markets caused by the inexorable COVID-19 pandemic, interest rate hikes in

the U.S. and other major countries that have spurred global price increases, and turmoil in the security environment driven by the Russian invasion of Ukraine. Taking these factors into consideration, along with the possibility of not being able to raise the necessary funding as expected in FY 2023 and beyond, the Company believes that securing the funding outlined in this document will strengthen and stabilize its financial foundations, raise its chances of evolving into a true global specialty pharmaceutical company, and contribute to an improvement in its corporate value. Further, the funds raised by the Company will be used as development funds for the antiviral drug brincidofovir, and to invest in new in-licensing and M&A for the purpose of securing long-term growth opportunities as described in "3. Amount to Be Raised, and the Use and Scheduled Disbursement Thereof." The Company had planned to allocate funds raised through the 58th stock acquisition rights to fulfill these purposes, but the exercise of the stock acquisition rights is not proceeding as planned as the exercise price is higher than the market price. Hence, we now intend to use the funds raised through the Program for the aforementioned purposes. If the amount to be paid in for each tranche of allotment under the Program falls below the exercise price for the 58th stock acquisition rights as of the due date of payment for the corresponding allotment, then the exercise price of the 58th stock acquisition rights will be revised to the payment amount for the said allotment. For details of the exercise price for the 58th stock acquisition rights, please see the Press Release on the Previous Capital Increase.

3. Amount to Be Raised, and the Use and Scheduled Disbursement Thereof

(1) Amount to Be Raised (Estimated Net Proceeds)

Total amount expected to be raised through the Program (estimated net proceeds)

1)	Expected total payment for new shares under the Program	¥2,208,000,000
2)	Approximate amount of various issuance-related expenses	¥24,400,000
3)	Estimated net proceeds	¥2,183,600,000

(Notes) 1. The amounts indicated above take into account the amounts to be paid for the issuance of shares in the 1st through 5th allotments, as detailed above in "I. STraight-Equity Issue Program ("STEP"). Of the total amount (estimate) indicated above, the breakdown below indicates the expected amounts for each allotment. We have assumed the issue of 1,200,000 shares for each allotment. This figure is a provisional calculation based on the simple average of the closing price of common shares of the Company in ordinary trading announced by the TSE during the 10 trading days up to and including October 5, 2023 (¥368, rounded off to the first decimal place). The number of shares for each allotment will range from 1,200,000 shares to 2,500,000 shares, and the total will not exceed the 6,000,000 shares stipulated for issuance under the Program. The actual number will be determined by the Allottee notifying the Company prior to the Allotment Resolution Date corresponding to each allotment. The issue price for each allotment is expected to be the amount equal to the simple average of the closing price of common shares of the Company announced by the TSE during the 10 trading days up to and including the day preceding the Allotment Resolution Date (rounded off to the first decimal place).

1) Expected total payment for shares issued in the 1st allotment: ¥441,600,000
2) Expected total payment for shares issued in the 2nd allotment: ¥441,600,000
3) Expected total payment for shares issued in the 3rd allotment: ¥441,600,000
4) Expected total payment for shares issued in the 4th allotment: ¥441,600,000
5) Expected total payment for shares issued in the 5th allotment: ¥441,600,000

2. The approximate amount of various issuance-related expenses is the approximate amount of various issuance-related expenses required for the entire Program.
3. The approximate amount of various issuance-related expenses breaks down into legal fees and notification form data preparation fees, fees for registration with the Legal Affairs Bureau, and various other fees (such as judicial scrivener fees, credit check fees, etc.).
4. The approximate amount of various issuance-related expenses does not include consumption and other taxes.

(2) Specific Uses of the Amount to Be Raised

The proceeds from the Program are to be used for the following specific purposes. The proceeds will be kept in bank deposits until they are used for the above purposes.

Specific uses	Amount (Million yen)	Expected timing of expenditure
(1) Development funds for antiviral drug brincidofovir (direct expenses)	658	October 2023 to June 2024
(2) Development funds for antiviral drug brincidofovir (indirect expenses)	742	October 2023 to June 2024
(3) Investment in new in-licensing and M&A for the purpose of securing long-term growth opportunities	783	October 2023 to June 2024
Total	2,183	

(Note) The description above indicates the use of funding raised by the Program overall. For details of the Program, please refer to “I. STraight-Equity Issue Program “STEP”)” above. Proceeds expected to be raised under the Program as a whole are stated above as ¥2,183,600,000, which is the total amount to be raised under the Program, of ¥2,208,000,000, less the estimated amount of various issuance-related expenses required under the overall Program, of ¥24,400,000. The total amount to be raised under the Program (¥2,208,000,000) is an estimate based on the simple average of the closing price of common shares of the Company in ordinary trading announced by the TSE during the 10 trading days up to and including October 5, 2023 (¥368, rounded off to the first decimal place). The actual amounts raised from the 1st through 5th allotments will be based on the issue price for each allotment, determined as the amount equal to the simple average of the closing price of common shares of the Company announced by the TSE during the 10 trading days up to and including the day immediately preceding the Allotment Resolution Date (rounded off to the first decimal place). The total amount of funds raised under the Program, the approximate amount of various issuance-related expenses, and estimated net proceeds may increase or decrease depending on the determination of the amount to be paid in and the number of new shares to be issued.

Details on the uses of funds raised are provided below.

1) Development funds for antiviral drug brincidofovir (direct expenses)

SymBio plans to use the development funds for antiviral drugs to cover the following expenses: among the development funds for the intravenous formulation of the antiviral drug brincidofovir (IV

BCV) in-licensed by the Company in September 2019, (1) direct expenses associated with the Phase II clinical trials for IV BCV already underway in the U.S. aimed at developing a treatment for adenovirus infections after hematopoietic stem cell transplants; (2) in the development of brincidofovir for BK virus infection after kidney transplants, expenses for clinical trials in Australia and Japan; and (3) development and other expenditures for a Phase I clinical trial targeting cytomegalovirus infection following hematopoietic stem cell transplantation.

Of this amount, expenditures of ¥658 million from October 2023 to June 2024 will be funded by the issuance of the Shares.

2) Expenses related to development of antiviral drug brincidofovir (indirect expenses)

SymBio forecasts expenditures in connection with efforts to strengthen its personnel, organization, and other areas to develop the intravenous formulation of the antiviral drug brincidofovir (IV BCV) for multiple indications, and in the form of indirect expenses for efforts to reinforce the organization, including the hiring of CEO and global CMO for the full-scale operation of U.S. subsidiary SymBio Pharma USA.

Of the above, it will cover ¥742 million in expenditures from October 2023 to June 2024 with the funds raised from the issuance of the Shares.

3) Investment funds for in-licensing and M&A for the purpose of securing long-term growth opportunities

From a medium- to long-term perspective, SymBio continues to search for and evaluate new drug candidates for potential in-licensing, and is routinely considering multiple license candidates, aiming to evolve into a profitable biopharmaceutical company with growth potential. As of the end of September 2023, its Scientific Advisory Board (SAB) had finished its evaluation for several products, and the Company is internally considering whether to acquire relevant licenses. It forecasts expenditures of ¥783 million for in-licensing and other expenses between October 2023 and June 2024.

For investment in new in-licensing and M&A for the purpose of securing long-term growth opportunities, the funds will first be apportioned at the time license agreements are concluded, and any expenses exceeding the expected amount to be raised shall be provided by internal funds. The Company has no specific plans for M&A as of the time of the release. As the amount and timing of funding will be affected by the state of progress for the Program, the aforementioned uses and breakdown of funds may change.

Further, the possibility exists that fundraising under the Program may not be exercised in part depending on such factors as the share price and trading volume.

If SymBio cannot procure sufficient funds through the Program, funds will be allocated in the following order of priority: 1) development funds for antiviral drug brincidofovir (direct expense), 2) expenses related to development of antiviral drug brincidofovir (indirect expenses), and 3) investment funds for in-licensing and M&A for the purpose of securing long-term growth opportunities. Further, it may procure funds through other measures or review its business plans. In the event of changes in the uses and breakdown of funds, the pursuit of separate funding, or revisions to its business plans, the Company will promptly disclose such information in each case.

SymBio expects to hold the funds above in its deposit account until apportioned for the uses of funds mentioned above.

On October 6, 2023, SymBio resolved to introduce the Program, with the aim of deploying funds for

the aforementioned uses.

4. Concepts on Rationality of the Use of the Funds

As described above in “3. Amount to Be Raised, and the Use and Scheduled Disbursement Thereof,” we have determined that the stated use of funds is rational and aligns with our strategy to invest in future growth areas and ensure financial stability. Accordingly, we believe that the Capital Increase by Third-Party Allotment will contribute to the interests of existing shareholders and other stakeholders by enhancing the Company’s corporate value over the medium to long term.

5. Rationality of Issuance Conditions

(1) Basis for Calculation of the Amount to Be Paid in and Details Thereof

The issue price for each allotment of the Shares will be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the TSE during the 10 trading days up to and including the day immediately preceding the Allotment Resolution Date (rounded off to the first decimal place). We cannot rule out the possibility that the issue price for each allotment of the Shares may fall below 90% of the closing price of the trading day immediately preceding each corresponding Allotment Resolution Date. The decision to set the period for determining the issue price at 10 trading days, rather than determining the price based on the share price at a specific point in time, i.e., the closing price of the business day immediately preceding the Allotment Resolution Date, was proposed by the Allottee as a more fair and reasonable method, as doing so would eliminate the impact of temporary share price fluctuations, and agreed to by the Company after consideration on both sides. Both parties also agreed to implement the five-tranche funding schedule as it allows for the comparison of share prices in the most recent month, three months, and six months over as short a period as possible.

In addition to the aforementioned factors, when determining the issue price SymBio engaged in frank discussions and negotiations with the Allottee, taking into consideration the Company’s performance trends, financial condition, and share liquidity, as well as analyzing recent stock prices and the process of forming those prices. Although the Company’s current stock price adequately reflects its objective corporate value at this time, as a result of our discussions we decided to stagger the timing of stock issuance and price determination after considering the risks that the Allottee would bear based on the assumption of holding a quantity of shares through the Capital Increase by Third-Party Allotment, taking into account the Company’s performance, financial condition, and stock price trends (volatility in the last six months: 32.77%), as well as the fact that the Allottee is the only party proposing this funding method through the third-party allotment of common shares of the Company.

Considering its business and financial situation, SymBio has determined that issuing the Shares is essential for improving performance and enhancing corporate value. We believe it is a crucial part of our business strategy and does not constitute a “favorable issuance.” The basis of calculation for the above payment amount is determined for each allotment by the Allotment Resolution, which is the “Board of Directors decision to issue the Shares” as defined by the “Guidelines Concerning Treatment of Capital Increase by Allotment to a Third Party” of the Japan Securities Dealers Association. The issuance of the Shares for each tranche, with the issue price being 100% of the average closing price during a certain period up to the trading day immediately preceding the date of the resolution, is deemed to be determined in consideration of the “Guidelines Concerning Treatment of Capital Increase by Allotment to a Third Party” to a certain degree. We have made this decision in full consultation with the Allottee.

Regarding this matter, the Company's Audit & Supervisory Committee (all three members are outside directors) concurs that, in using the above basis for calculating the issue price, the above-stated calculation method is appropriate, as it uses the market price as an indicator expressing the objective value of the Company's shares and considering the need for conducting this capital increase through third-party allotment, as well as the Company's performance trends, financial situation, the current state of the stock market, trends in the Company's share price, and the number of shares expected to be issued through this capital increase through third-party allotment. Furthermore, considering that the guidelines of the Japan Securities Dealers Association were referred to when determining the calculation method, the committee has concluded that the issue price is not particularly advantageous to the Allottee. The Company plans to obtain the opinion of the Audit & Supervisory Committee regarding the payment amount to be resolved on the Allotment Resolution Date corresponding to each allotment.

(2) Grounds for a Judgment That the Issued Quantity and the Scale of the Dilution of Shares Are Reasonable

As is stated above in "I. STraight-Equity Issue Program ("STEP"), 1. Details of the Program," the number of common shares of the Company to be newly issued under the Program is capped at 6,000,000 shares (60,000 voting rights). This corresponds to a dilution rate of 15.06%, using as a denominator the total number of SymBio's shares issued as of June 30, 2023, of 39,840,556 shares, and 393,555 voting rights (dilution rate based on voting rights of 15.25%).

However, by allocating the funds raised through the Program for the intended uses as outlined in "3. Amount to Be Raised, and the Use and Scheduled Disbursement Thereof," the Company aims to invest in areas slated for future growth and ensure a stable financial base, which it believes will result in increases in corporate value and share price. As a result, the Company has determined that the number of shares to be issued and the scale of dilution for its shares are reasonable.

Further, the average daily trading volume of the common shares of the Company over the past six months was 430,364 shares, indicating sufficient liquidity to sell shares in the market. Assuming the maximum number of shares under the Program is issued (6,000,000 shares), selling these shares during the 131 trading days from the date of this release until the due date of payment for the 5th allotment would mean the sale of an average of 45,802 shares per trading day (10.64% of average trading volume during the past six months), so we believe the impact on the share price would be limited. In addition, this issuance would provide the funding the Company needs to conduct its business operations with a relatively high probability of success.

6. Reasons for Having Chosen the Allottee, etc.

(1) Outline of the Allottee

Please refer to the above section entitled "I. STraight-Equity Issue Program ("STEP"), 4. Reasons for Having Chosen the Allottee, etc., (1) Outline of the Allottee."

(2) Reason for Having Chosen the Allottee

Please refer to the above section entitled "I. STraight-Equity Issue Program ("STEP"), 4. Reasons for Having Chosen the Allottee, etc., (2) Reason for Having Chosen the Allottee."

(3) Allottee's Holding Policy

Please refer to the above section entitled "I. STraight-Equity Issue Program ("STEP"), 4. Reasons for

Having Chosen the Allottee, etc., (3) Allottee's Holding Policy."

(4) Confirmation on the Property Required for the Payment by the Allottee

As evidence of property held by the Allottee, SymBio has confirmed the Allottee's net asset balance statement, excluding liabilities from such assets as cash and marketable securities borrowed from multiple prime brokers as of July 31, 2023, and SymBio judges that the Allottee maintains sufficient cash to pay the total amount to be paid (issue price) for the 1st allotment on the due date of payment.

(5) Agreement regarding borrowing and lending of share certificates

In connection with the issuance of the Shares, the Allottee may enter into a stock lending agreement with Fuminori Yoshida, who is both a major shareholder of the Company and its representative director, president, and chief executive officer (contract period: October 6, 2003 to May 2, 2024, number of shares for lending: 1,179,700 shares, lending fee: 0% per annum, collateral: none), borrowing common shares of the Company that it may sell for the purpose of hedging.

The Allottee will not borrow common shares of the Company for the purpose of engaging in any short-selling activities, except for selling for hedging purposes within the quantity of common shares of the Company issued through each allotment. Based on the Agreement to Set up an Equity Issue Program between SymBio and the Allottee, the Allottee will not engage in the short-selling of borrowed common shares of the Company other than selling for hedging purposes within the quantity of common shares of the Company issued through each allotment.

7. Major Shareholders and Shareholding Ratios

Before offer (as of June 30, 2023)	
Shareholder	Shareholding ratio (%)
Fuminori Yoshida	2.97
ML PRO SEGREGATION ACCOUNT (Standing proxy: BofA Securities Japan Co, Ltd.	2.51
Norihiro Kuroda	1.77
Sukenori Ito	1.08
MSIP CLIENT SECURITIES (Standing proxy: Morgan Stanley MUFG Securities Co., Ltd.)	0.87
Toshitaka Kashihara	0.55
SMBC Nikko Securities Inc.	0.31
Tsugino Fujimoto	0.30
Hiroshi Nishioka	0.30
Hiromi Toshige	0.29

(Notes) 1. Shareholding ratios prior to allotment are based on the shareholder register as of June 30, 2023.

2. The Allottee shall hold the common shares of the Company for the purpose of investment, and may sell the common shares of the Company acquired. As the Allottee is not committed to long-term ownership of the common shares of the Company, its post-allotment shareholding ratio is not shown.

3. Shareholding ratios are rounded off to the second decimal place.

8. Future Perspective

The Capital Increase by Third-Party Allotment will not affect operating performance in the current fiscal year (the fiscal year ending December 31, 2023). SymBio will disclose promptly in the event of changes in future business performance.

9. Matters Relating to Procedures Based on the Code of Conduct of Corporations

As dilution of SymBio's shares by capital increase through a series of third-party allotments under the Program will result in a dilution ratio of less than 25% and because it will not give rise to changes in controlling shareholders, there is no need to obtain an opinion from an independent third party on "compliance requirements for third-party allotment" or to conduct a procedure to confirm the intent of shareholders as set forth in Article 432 of the Securities Regulations of the TSE.

10. Business Performance and Equity Finances for the Most Recent Three Years

(1) Operating Results for the Most Recent Three Years

	FY 2020	FY 2021	FY 2022
Net sales (Thousands of yen)	2,987,051	8,256,924	10,008,338
Operating profit (Thousands of yen)	(4,506,220)	1,016,001	1,963,625
Ordinary profit (Thousands of yen)	(4,615,903)	1,001,133	1,999,878
Profit (Thousands of yen)	(4,090,216)	2,032,203	1,179,238
Earnings per share (Yen)	(124.13)	53.04	30.20
Dividends per share (Yen)	—	—	—
Net assets per share (Yen)	105.76	162.26	204.83

(Note) The Company began preparing consolidated statements of income from the fiscal year ended December 31, 2022 with the launch of full-scale operations at SymBio Pharma USA, Inc. For fiscal years prior to that, figures from non-consolidated statements of income are provided.

(2) Number of Issued Shares and Dilutive Shares (As of June 30, 2023)

	Number of shares	Percentage relative to the number of issued shares
Number of shares issued	39,840,556	100.00%
Number of dilutive shares at the conversion price (exercise price) at present	2,229,450	5.60%
Number of dilutive shares at the lower-limit of the conversion price (exercise price)	—	—
Number of dilutive shares at the upper-limit of the conversion price (exercise price)	—	—

(3) Recent Share Prices

1) For the most recent three years

	FY 2020	FY 2021	FY 2022
Opening price	¥600	¥384	¥1,150
Highest price	¥653	¥2,566	¥1,290
Lowest price	¥243	¥372	¥606
Closing price	¥379	¥1,145	¥643

(Note) Share prices are according to the TSE.

2) For the most recent six months

	May 2023	June 2023	July 2023	August 2023	September 2023	October 2023
Opening price	¥398	¥425	¥436	¥415	¥391	¥383
Highest price	¥464	¥483	¥442	¥422	¥408	¥383
Lowest price	¥356	¥407	¥414	¥371	¥361	¥344
Closing price	¥431	¥436	¥418	¥392	¥380	¥350

(Notes) 1. Share prices are according to the TSE.

2. Share prices for October 2023 are those as of October 5, 2023.

3) Share prices on the business day preceding the date on which the Board of Directors resolved the issuance

	As of October 5, 2023
Opening price	¥345
Highest price	¥353
Lowest price	¥344
Closing price	¥350

(4) Equity Finances for the Most Recent Three Years

Issuance of new shares by third-party allotment and the 58th Stock Acquisition Rights

(New shares)

Date of payment	June 1, 2022
Amount of funding	¥662,000,000 (net ¥622,000,000)
Issue price	¥662
Number of issued shares at the time of offer	38,486,156 shares
Number of shares issued through this offer	1,000,000 shares
Number of issued shares after the offer	39,486,156 shares
Allottee	CVI Investments, Inc.
Initial use of funds at the time of issuance	(1) Development funds for the antiviral drug brincidofovir (direct expenses) (¥432 million)

Note: This document does not constitute an investment solicitation for any securities for sale. This document has been prepared to publicly announce matters related to the issuance of the common stock, and not for the purpose of soliciting investment. This document does not constitute an offer of investment in nor solicitation for purchase of the common stock within the United States. Regarding the common stock, SymBio has not registered, and is not scheduled to register, any of them under the United States Securities Act of 1933. The securities may not be offered or sold in the United States without a registration or an exemption from registration under the United States Securities Act of 1933. No offer of securities in the United States will be made in connection with this transaction.

	(2) (As above, indirect expenses) (¥190 million)
Planned timing for disbursement at the time of issuance	(1) From July 2022 to October 2022 (2) From July 2022 to October 2022
Appropriation status at present	(1) Development funds for the antiviral drug brincidofovir (direct expenses) (¥432 million) (2) (As above, indirect expenses) (¥190 million)

(58th stock acquisition rights)

Date of allotment	June 1, 2022
Number of stock acquisition rights issued	20,000 unit
Issue price*	Total of ¥13,760,000 (¥688 for each unit of the stock acquisition rights)
Planned amount of funding at the time of issuance (estimated net proceeds)	¥1,583,760,000
Allottee	CVI Investments, Inc.
Number of issued shares at the time of offer	38,486,156 shares
Number of dilutive shares due to the offer	Number of dilutive shares: 2,000,000 shares
Exercise status at present	0 shares (Remaining stock acquisition rights: 20,000)
Procured funds at present (estimated net proceeds)	¥0
Initial intended use of funds at the time of issuance	(1) Development funds for the antiviral drug brincidofovir (direct expenses) (¥787 million) (2) (As above, indirect expenses) (¥386 million) (3) Investment in new in-licensing, M&A, and other means of securing long-term growth opportunities (¥395.76 million).
Planned timing for disbursement at the time of issuance	(1) From October 2022 to March 2023 (2) From October 2022 to March 2023 (3) From July 2022 to March 2023
Appropriation status at present	(N/A)

(Note) If the amount to be paid in for each tranche of allotment under the Program falls below the exercise price as of the due date of payment for the corresponding allotment, then the exercise price will be revised to the payment amount for the said allotment. Planned timing for disbursement will be revised when a request to exercise the stock acquisition rights is made, and accordingly, we will decide by how much to revise the planned timing for disbursement when such a request is made and make a disclosure.

12. Issuance Terms and Conditions

As per the attachments.

Attachment 1

Terms and Conditions Related to the 1st Allotment

1. Class of Shares Offered
   Common shares of the Company

2. Number of Shares Offered
   1,200,000~2,500,000 shares

3. Issue Price (Amount to Be Paid In under the Companies Act)
   The price per share shall be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the Tokyo Stock Exchange, Inc. during the 10 trading days up to and including the day preceding October 25, 2023 (rounded off to the first decimal place). (However, if there is no closing price for any of the 10 trading days, EVO FUND may decide whether to include such a day in the calculation of the issue price.)

4. Total Issue Price (Amount to Be Paid In under the Companies Act)
   The amount equal to the number of shares offered times the issue price per share

5. Increases in Capital Stock and Legal Capital Surplus
   The amount to be contributed to capital stock shall be half the upper limit of an increase in capital stock under Article 14, Paragraph 1, of the Rules of Corporate Accounting (with any fractional amounts less than one yen resulting from such calculation rounded up). The increase in the legal surplus shall be the upper limit of an increase in capital stock less the amount of the increase in capital stock.

6. Deadline for Application
   November 10, 2023

7. Due Date of Payment
   November 10, 2023

8. Method of Offer
   All shares are to be allotted to EVO FUND through a third-party allotment.

9. (1) The above paragraphs shall apply on the condition that the notification in accordance with the Financial Instruments and Exchange Act becomes effective.
   (2) Other necessary matters related to this new share issuance shall be entrusted to the representative director and CEO of SymBio.

Attachment 2

Terms and Conditions Related to the 2nd Allotment

1. Class of Shares Offered
   Common shares of the Company

2. Number of Shares Offered
   1,200,000~2,500,000 shares

3. Issue Price (Amount to Be Paid In under the Companies Act)
   The price per share shall be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the Tokyo Stock Exchange, Inc. during the 10 trading days up to and including the day preceding December 4, 2023 (rounded off to the first decimal place). (However, if there is no closing price for any of the 10 trading days, EVO FUND may decide whether to include such a day in the calculation of the issue price).

4. Total Issue Price (Amount to Be Paid In under the Companies Act)
   The amount equal to the number of shares offered times the issue price per share

5. Increases in Capital Stock and Legal Capital Surplus
   The amount to be contributed to capital stock shall be half the upper limit of an increase in capital stock under Article 14, Paragraph 1, of the Rules of Corporate Accounting (with any fractional amounts less than one yen resulting from such calculation rounded up). The increase in the legal surplus shall be the upper limit of an increase in capital stock less the amount of the increase in capital stock.

6. Deadline for Application
   December 20, 2023

7. Due Date of Payment
   December 20, 2023

8. Method of Offer
   All shares are to be allotted to EVO FUND through a third-party allotment.

9. (1) The above paragraphs shall apply on the condition that the notification in accordance with the Financial Instruments and Exchange Act becomes effective.
   (2) Other necessary matters related to this new share issuance shall be entrusted to the representative director and CEO of SymBio.

Attachment 3

Terms and Conditions Related to the 3rd Allotment

1. Class of Shares Offered
Common shares of the Company

2. Number of Shares Offered
1,200,000~2,500,000 shares

3. Issue Price (Amount to Be Paid In under the Companies Act)
The price per share shall be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the Tokyo Stock Exchange, Inc. during the 10 trading days up to and including the day preceding January 22, 2024 (rounded off to the first decimal place). (However, if there is no closing price for any of the 10 trading days, EVO FUND may decide whether to include such a day in the calculation of the issue price).

4. Total Issue Price (Amount to Be Paid In under the Companies Act)
The amount equal to the number of shares offered times the issue price per share

5. Increases in Capital Stock and Legal Capital Surplus
The amount to be contributed to capital stock shall be half the upper limit of an increase in capital stock under Article 14, Paragraph 1, of the Rules of Corporate Accounting (with any fractional amounts less than one yen resulting from such calculation rounded up). The increase in the legal surplus shall be the upper limit of an increase in capital stock less the amount of the increase in capital stock.

6. Deadline for Application
February 7, 2024

7. Due Date of Payment
February 7, 2024

8. Method of Offer
All shares are to be allotted to EVO FUND through a third-party allotment.

9. (1) The above paragraphs shall apply on the condition that the notification in accordance with the Financial Instruments and Exchange Act becomes effective.
(2) Other necessary matters related to this new share issuance shall be entrusted to the representative director and CEO of SymBio.

Attachment 4

Terms and Conditions Related to the 4th Allotment

1. Class of Shares Offered
Common shares of the Company

2. Number of Shares Offered
1,200,000~2,500,000 shares

3. Issue Price (Amount to Be Paid In under the Companies Act)
The price per share shall be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the Tokyo Stock Exchange, Inc. during the 10 trading days up to and including the day preceding February 29, 2024 (rounded off to the first decimal place). (However, if there is no closing price for any of the 10 trading days, EVO FUND may decide whether to include such a day in the calculation of the issue price).

4. Total Issue Price (Amount to Be Paid In under the Companies Act)
The amount equal to the number of shares offered times the issue price per share

5. Increases in Capital Stock and Legal Capital Surplus
The amount to be contributed to capital stock shall be half the upper limit of an increase in capital stock under Article 14, Paragraph 1, of the Rules of Corporate Accounting (with any fractional amounts less than one yen resulting from such calculation rounded up). The increase in the legal surplus shall be the upper limit of an increase in capital stock less the amount of the increase in capital stock.

6. Deadline for Application
March 18, 2024

7. Due Date of Payment
March 18, 2024

8. Method of Offer
All shares are to be allotted to EVO FUND through a third-party allotment.

9. (1) The above paragraphs shall apply on the condition that the notification in accordance with the Financial Instruments and Exchange Act becomes effective.
(2) Other necessary matters related to this new share issuance shall be entrusted to the representative director and CEO of SymBio.

Attachment 5

Terms and Conditions Related to the 5th Allotment

1. Class of Shares Offered
Common shares of the Company

2. Number of Shares Offered
1,200,000~2,500,000 shares

3. Issue Price (Amount to Be Paid In under the Companies Act)
The price per share shall be the amount equal to the simple average of the closing price of common shares of the Company in ordinary trading announced by the Tokyo Stock Exchange, Inc. during the 10 trading days up to and including the day preceding April 3, 2024 (rounded off to the first decimal place). (However, if there is no closing price for any of the 10 trading days, EVO FUND may decide whether to include such a day in the calculation of the issue price.

4. Total Issue Price (Amount to Be Paid In under the Companies Act)
The amount equal to the number of shares offered times the issue price per share

5. Increases in Capital Stock and Legal Capital Surplus
The amount to be contributed to capital stock shall be half the upper limit of an increase in capital stock under Article 14, Paragraph 1, of the Rules of Corporate Accounting (with any fractional amounts less than one yen resulting from such calculation rounded up). The increase in the legal surplus shall be the upper limit of an increase in capital stock less the amount of the increase in capital stock.

6. Deadline for Application
April 19, 2024

7. Due Date of Payment
April 19, 2024

8. Method of Offer
All shares are to be allotted to EVO FUND through a third-party allotment.

9. (1) The above paragraphs shall apply on the condition that the notification in accordance with the Financial Instruments and Exchange Act becomes effective.
(2) Other necessary matters related to this new share issuance shall be entrusted to the representative director and CEO of SymBio.